Logo image of BCTX

BRIACELL THERAPEUTICS CORP (BCTX) Stock Fundamental Analysis

USA - NASDAQ:BCTX - CA1079303071 - Common Stock

13.79 USD
+0.65 (+4.95%)
Last: 10/24/2025, 8:10:29 PM
13.52 USD
-0.27 (-1.96%)
After Hours: 10/24/2025, 8:10:29 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BCTX. BCTX was compared to 534 industry peers in the Biotechnology industry. BCTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCTX had negative earnings in the past year.
BCTX had a negative operating cash flow in the past year.
In the past 5 years BCTX always reported negative net income.
In the past 5 years BCTX always reported negative operating cash flow.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

BCTX's Return On Assets of -123.71% is on the low side compared to the rest of the industry. BCTX is outperformed by 81.09% of its industry peers.
Looking at the Return On Equity, with a value of -321.51%, BCTX is doing worse than 72.10% of the companies in the same industry.
Industry RankSector Rank
ROA -123.71%
ROE -321.51%
ROIC N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K 1.5K

1.3 Margins

BCTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCTX has more shares outstanding
The number of shares outstanding for BCTX has been increased compared to 5 years ago.
There is no outstanding debt for BCTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

BCTX has an Altman-Z score of -18.90. This is a bad value and indicates that BCTX is not financially healthy and even has some risk of bankruptcy.
BCTX has a worse Altman-Z score (-18.90) than 84.27% of its industry peers.
BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.9
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BCTX has a Current Ratio of 1.37. This is a normal value and indicates that BCTX is financially healthy and should not expect problems in meeting its short term obligations.
BCTX's Current ratio of 1.37 is on the low side compared to the rest of the industry. BCTX is outperformed by 82.77% of its industry peers.
BCTX has a Quick Ratio of 1.37. This is a normal value and indicates that BCTX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BCTX (1.37) is worse than 82.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

BCTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -994.62%.
EPS 1Y (TTM)-994.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-199.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BCTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-431.62%
EPS Next 2Y-285.35%
EPS Next 3Y-79.83%
EPS Next 5Y-23.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

BCTX's earnings are expected to decrease with -79.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-285.35%
EPS Next 3Y-79.83%

More info and screens

0

5. Dividend

5.1 Amount

BCTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (10/24/2025, 8:10:29 PM)

After market: 13.52 -0.27 (-1.96%)

13.79

+0.65 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-16 2025-06-16/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners9.66%
Inst Owner Change0%
Ins Owners3.94%
Ins Owner Change0%
Market Cap25.93M
Revenue(TTM)N/A
Net Income(TTM)-11583600
Analysts80
Price TargetN/A
Short Float %5.15%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.6%
Min EPS beat(2)-172.28%
Max EPS beat(2)-18.91%
EPS beat(4)2
Avg EPS beat(4)3.82%
Min EPS beat(4)-172.28%
Max EPS beat(4)119.8%
EPS beat(8)5
Avg EPS beat(8)17.93%
EPS beat(12)6
Avg EPS beat(12)-15.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)43.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.2
P/tB 7.6
EV/EBITDA N/A
EPS(TTM)-83.2
EYN/A
EPS(NY)-11.56
Fwd EYN/A
FCF(TTM)-11.88
FCFYN/A
OCF(TTM)-11.64
OCFYN/A
SpS0
BVpS1.92
TBVpS1.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.71%
ROE -321.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z -18.9
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-994.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-199.39%
EPS Next Y-431.62%
EPS Next 2Y-285.35%
EPS Next 3Y-79.83%
EPS Next 5Y-23.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.83%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCTX FAQ

What is the ChartMill fundamental rating of BRIACELL THERAPEUTICS CORP (BCTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BCTX.


What is the valuation status for BCTX stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIACELL THERAPEUTICS CORP (BCTX). This can be considered as Overvalued.


What is the profitability of BCTX stock?

BRIACELL THERAPEUTICS CORP (BCTX) has a profitability rating of 0 / 10.


What is the expected EPS growth for BRIACELL THERAPEUTICS CORP (BCTX) stock?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCTX) is expected to decline by -431.62% in the next year.